Recursos de NCI

Anti-CD20 Antibody + Chemo Benefits CLL With Comorbidity

Jan 9, 2014 - For patients with previously untreated chronic lymphocytic leukemia and coexisting conditions, combining an anti-CD20 antibody (rituximab or obinutuzumab) with chemotherapy is associated with improved outcomes, according to a study published online Jan. 8 in the New England Journal of Medicine.

I Wish You Knew

How cancer patients have changed my life

View More

Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.

OncoLink OncoPilot

Frente a un nuevo diagnóstico de cáncer o de cambiar el curso de su tratamiento actual? Deje que nuestro personal de enfermería cáncer que ayudan a pasar!

Más información

OncoLink Cancer Treatment and Resources